Starget Pharma develops Smart Targeted Radioligands (STRs) using proprietary peptide backbone dynamics technology to deliver targeted radiation directly to tumoral and metastatic cancer cells, minimizing damage to healthy tissues. This approach addresses the need for effective treatment options in advanced metastatic cancers, offering a broader therapeutic window compared to traditional radiation therapies.
Funding
$19.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CFFounders
Product
Problem
Many advanced metastatic cancers lack effective treatment options, and traditional radiation therapies often damage healthy tissues due to their non-specific targeting. This necessitates treatment options that can selectively target cancer cells while minimizing off-target effects.
Solution
Starget Pharma is developing Smart Targeted Radioligands (STRs), a novel class of precision oncology therapeutics for hard-to-treat cancers. STRs utilize a proprietary peptide backbone dynamics technology to design radioligands that selectively deliver radiation directly to tumor and metastatic cancer cells. This targeted approach aims to maximize therapeutic efficacy while minimizing damage to healthy tissues, offering an improved therapeutic window compared to conventional radiation therapies. The company's AI-driven in silico platform simulates and optimizes 3D molecular conformations to identify drug-like radioligand candidates with enhanced affinity, selectivity, and pharmacokinetic properties. By transforming peptides into smart molecular vehicles, Starget Pharma seeks to accelerate the discovery and development of novel radioligands for a broad range of cancers.
Target Audience
The primary target audience includes patients with advanced metastatic cancers who have limited or non-existent treatment options, as well as oncologists and nuclear medicine specialists seeking more effective and targeted therapies.
Features
- AI-powered in silico platform for rapid discovery and design of novel peptide-based radioligands
- Proprietary peptide backbone dynamics technology for enhanced drug-like properties
- Tunable 2D/3D molecular diversity for targeting multiple cancer types
- Integrated approach from virtual screening to radioligand wet lab screening
- Peptide engineering for optimized affinity, selectivity, and bioavailability